Nanobodies Market Growth By Global Players Novo
Nordisk A/S, Merck & Co., Inc., Merck KGaA
Nanobodies are considered to be one of the best technology in the fields of research,
diagnostics and therapy especially in cancer research. These technology was developed from
antigen binding fragments, originating from Camelid heavy-chain antibodies. These molecules do
not have light chains, which is an essential part of antibodNanobodies Market Growth By
Global Players Novo Nordisk A/S, Merck & Co., Inc., Merck KGaAy found in humans. Based on
the above finding, nanobodies molecule containing single-domain only were developed, and
these molecules contain functional and structural properties similar to heavy chain antibodies.
These molecules have several advantages as compared to the conventional antibodies such as
small-size, nano to picomolar affinities, and multiple route of administration. Ablynx, which is
acquired by Sanofi S.A., is one of the leading company in this market.
Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/1680
Nanobodies Market Drivers
Currently, no products are available in the market, but there are multiple products in the
pipeline including few in very late stage of clinical trials. For instance, marketing authorization
application for Caplacizumab for the treatment of acquired thrombotic thrombocytopenic
purpura (aTTP) has been submitted to European Medicine Agency (EMA) in February 2017. The
product, Caplacizumab, is expected to be launched in Europe in 2018. Moreover, the company,
Ablynx, is expected to file for biologic license agreement to the U.S. Food and Drug
Administration (FDA) in 2018, and is expected to launch this product in U.S. in 2019. Both,
Europe and U.S. are the key markets for any biologics including monoclonal antibodies and are
expected to be the high revenue generating market for nanobodies. Hence, approval by
regulatory bodies in Europe and U.S. to Caplacizumab in very near future (i.e. 2018, 2019) is
expected to drive the growth of global nanobodies market. As per the company, Ablynx,
estimates the product has potential to generate more than US$ 1 Bn. Furthermore, there are
multiple products in early stage of clinical development i.e. preclinical, phase 0, and phase 1.
Ablynx alone had 8 products in clinical development phase (i.e. phase 0 to phase 3) and overall
45 products in pipeline as of March 2017.